Bessemer Group Inc. Grows Position in Kenvue Inc. $KVUE

Bessemer Group Inc. raised its stake in shares of Kenvue Inc. (NYSE:KVUE) by 0.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,525,023 shares of the company’s stock after purchasing an additional 33,680 shares during the period. Bessemer Group Inc. owned 0.44% of Kenvue worth $146,972,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Physician Wealth Advisors Inc. grew its stake in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after buying an additional 618 shares during the period. Elyxium Wealth LLC purchased a new position in shares of Kenvue in the 4th quarter worth $26,000. MV Capital Management Inc. purchased a new position in shares of Kenvue in the 4th quarter worth $28,000. Reflection Asset Management acquired a new position in Kenvue in the fourth quarter valued at $32,000. Finally, SBI Securities Co. Ltd. boosted its holdings in Kenvue by 82.4% in the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after acquiring an additional 1,027 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 1.8%

Shares of Kenvue stock opened at $19.03 on Friday. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $22.87. The stock has a market cap of $36.55 billion, a price-to-earnings ratio of 22.39, a price-to-earnings-growth ratio of 1.42 and a beta of 0.47. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The company has a fifty day moving average price of $18.17 and a 200 day moving average price of $17.85.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm’s revenue was up 4.5% compared to the same quarter last year. During the same period last year, the company posted $0.24 earnings per share. Equities research analysts forecast that Kenvue Inc. will post 1.16 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were paid a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is 97.65%.

Insider Activity at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.59% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on KVUE. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. UBS Group lifted their price objective on Kenvue from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday. Wall Street Zen upgraded Kenvue to a “buy” rating in a report on Sunday, July 12th. Citigroup decreased their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Finally, Zacks Research lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat.com, Kenvue presently has an average rating of “Hold” and a consensus target price of $19.50.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.